Peptidoglycan-associated lipoprotein (Pal) is one component of the Tol-Pal system that is involved in maintaining the integrity and stability of the outer membrane. The C-terminal OmpA-like domain of Pal interacts noncovalently with peptidoglycan. In this study, the OmpA-like domain of Pal from Acinetobacter baumannii was overexpressed in Escherichia coli strain BL21 (DE3), purified and crystallized using the vapour-diffusion method. A native crystal diffracted to 1.4 Å resolution and belonged to space group P6 1 or P6 5 , with unit-cell parameters a = b = 72.58, c = 44.65 Å , a calculated Matthews coefficient of 2.64 Å 3 Da À1 and one molecule per asymmetric unit.
Introduction
Peptidoglycan-associated lipoprotein (Pal) of Gram-negative bacteria is one component of the Tol-Pal system, which plays an important role in the integrity of the outer membrane (OM; Gerding et al., 2007; Godlewska et al., 2009; Yeh et al., 2010) . The Tol-Pal system is composed of five proteins encoded by two operons: TolQ, TolR and TolA from the orf1-tolQ-tolR-tolA operon form a protein complex in the inner membrane, while TolB and Pal from the tolB-pal-orf2 operon form an OM-associated complex in the periplasmic space (Dubuisson et al., 2005; Godlewska et al., 2009; Muller & Webster, 1997; Vianney et al., 1996) . Escherichia coli Pal (EcPal) is released during sepsis-induced inflammation and plays a significant role in bacterial infections (Hellman et al., 2002) .
Acinetobacter baumannii is an opportunistic pathogen that induces cytotoxicity in host cells by nosocomial infection of compromised patients (Bergogne-Bé ré zin & Towner, 1996; Choi et al., 2005; Dent et al., 2010) . Full-length A. baumannii Pal (AbPal) shares 38% aminoacid sequence identity with EcPal. AbPal is composed of an N-terminal motif that is required for delivery and anchoring to the OM and a C-terminal OmpA-like domain. AbPal is found in the outer membrane vesicle (OMV) used to deliver virulence effectors into host cells (Jin et al., 2011; Yun et al., 2011) . However, the direct role of AbPal in pathogenesis has not yet been investigated.
Generally, OmpA-like domain proteins interact noncovalently with peptidoglycan in the periplasm of Gram-negative bacteria, as shown in the structure of the OmpA-like domain from A. baumannii OmpA (AbOmpA-PD; Park et al., 2012) . Although a solution structure of the OmpA-like domain of Pal protein in complex with a peptide fragment of peptidoglycan has been determined (Parsons et al., 2006) , its detailed atomic structure in complex with peptidoglycan components will be helpful in understanding the structural role played by Pal in OM integrity. Here, we report the crystallization and preliminary X-ray crystallographic analysis of the OmpA-like domain of AbPal.
Materials and methods

Cloning and recombinant protein purification
The DNA sequence encoding the OmpA-like domain of Pal (AbPal-71; residues 71-181; molecular mass 12.5 kDa) was amplified via polymerase chain reaction (PCR) using genomic DNA from # 2012 International Union of Crystallography All rights reserved A. baumannii 19606 with the primers 5 0 -ACTCATATGGAGTTA-ACTGAAGACCTTAACATGG-3 0 and 5 0 -ACTCTCGAGTTAAC-GGCTACCAGTGATTGTCG-3 0 . To generate an N-terminally His 6tagged fusion protein, the PCR product was cloned into the NdeI/ XhoI-digested expression vector pET-28a(+) (Novagen). The resulting plasmid was transformed into the expression host E. coli BL21 (DE3) and bacterial cells were grown at 310 K until the OD 600 reached 0.5-0.6 in Luria-Bertani (LB) medium containing 50 mg ml À1 kanamycin. The expression of recombinant AbPal-71 was induced using 1 mM isopropyl -d-1-thiogalactopyranoside at 291 K for 18 h. Bacterial cells were harvested by centrifugation at 5000 rev min À1 for 20 min at 277 K.
AbPal-71 protein was prepared as described previously . The protein was initially isolated using a nickel-affinity column. After thrombin digestion, AbPal-71 was further purified using gel-filtration chromatography (Superdex 75 HiLoad 16/60 prep grade, GE Healthcare). The purified protein was concentrated to a final concentration of 20 mg ml À1 in 50 mM bis-Tris pH 6.5, 100 mM glycine by ultrafiltration using an Amicon Ultra 10 kDa cutoff filter (Millipore) and stored at 193 K until use in crystallization experiments.
Crystallization
Initial crystallization screening by the sitting-drop vapour-diffusion method was performed using various screening kits (Crystal Screen HT and Index HT from Hampton Research and Wizard Classic 1 and 2 from Emerald BioSystems) at 293 K. A Mosquito crystallization robot (TTP LabTech) was used for initial screening trials. From initial screening, it was found that formulations with salt precipitants such as sodium formate, sodium chloride, ammonium phosphate or sodium/ potassium phosphate prompted the crystallization of AbPal-71. After several hits were obtained from the initial screening, crystallizationcondition optimization experiments were carried out by the hangingdrop vapour-diffusion method using condition No. 19 from Wizard Classic 1 and yielded crystals suitable for X-ray diffraction study. In the final optimization, 1 ml protein solution consisting of 20 mg ml À1 protein in 50 mM bis-Tris pH 6.5, 100 mM glycine was mixed with 1 ml reservoir buffer (0.1 M phosphate-citrate pH 4.2, 0.4 M K 2 HPO 4 , 1.0-1.4 M NaH 2 PO 4 ) and equilibrated by vapour diffusion against the reservoir solution. Clusters of rod-shaped crystals grew within one week to dimensions of 0.05 Â 0.05 Â 0.5 mm and were suitable for X-ray analysis.
X-ray data collection
The crystals grew as clusters of rod-shaped crystals and a single crystal had to be separated prior to data collection. A detached single crystal of suitable size was transferred into reservoir buffer supplemented with 20%(v/v) glycerol as a cryoprotectant and mounted on a CryoLoop (Hampton Research) for diffraction studies under cryogenic conditions. X-ray diffraction tests to screen crystals for the synchrotron trip were performed using a MicroMax-007 HF rotatinganode X-ray generator and an R-AXIS IV ++ imaging-plate area detector (Rigaku, Japan). Final diffraction data were collected on the BL-17A beamline at the Photon Factory, Tsukuba, Japan. A total of 90 frames of images with an oscillation angle of 1 were collected on an ADSC Quantum 315r detector (Area Detector Systems Corporation, USA). The beam slit size was 0.05 Â 0.05 mm. The diffraction images were integrated and scaled using HKL-2000 (Otwinowski & Minor, 1997) .
Results and discussion
The OmpA-like domain of AbPal (AbPal-71; molecular weight 12.5 kDa) was cloned into pET28a vector containing an N-terminal hexahistidine tag followed by a thrombin protease cleavage site and overexpressed in E. coli BL21 (DE3) cells. After purification using a nickel-affinity column and subsequent size-exclusion chromatography, the homogeneity of the purified protein was verified by SDS-PAGE, showing >95% purity. The results of gel-filtration chromatography suggested that AbPal-71 is monomeric in solution (data not shown). Initial screening for crystallization conditions was performed by the sitting-drop vapour-diffusion method using commercially available screening kits. Based on hits from the initial screening, crystallization conditions were manually optimized and clusters of rod-shaped crystals were obtained (Fig. 1) . A native AbPal-71 crystal diffracted to beyond 1.4 Å resolution using synchrotron radiation (Fig. 2) . Upon processing the X-ray diffraction data, the native AbPal-71 crystal was found to belong to space group P6 1 or P6 5 , with unit-cell parameters a = b = 72.58, c = 44.65 Å , = = 90, = 120 (Table 1 ). The Matthews coefficient was 2.64 Å 3 Da À1 and the solvent content was 53.4%, assuming that the asymmetric unit contained one molecule of AbPal (Matthews, 1968) .
The OmpA-like domain of AbPal shares $50% amino-acid sequence identity with EcPal, for which a crystal structure has been determined (PDB entry 1oap; C. Abergel, A. Walburger, E. Bouveret & J.-M. Claverie, unpublished work), in contrast to only $26% sequence identity with AbOmpA-PD. Given their similar role in peptidoglycan binding, comparing the structures of AbPal and AbOmpA-PD will reveal valuable structural insights into the distinct functional aspects of each protein. In conclusion, our preliminary X-ray data will be useful for further structural characterization of the OmpA-like domain of AbPal. Structure determination by molecular replacement using the structure of EcPal and cocrystallization experiments with peptidoglycan fragments are currently under way. 
